5 Simple Statements About ABBV-744 clinical trial phase 1 results Explained
In Segment C, individuals will receive ABBV-744 and oral navitoclax. In Section D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment right until disorder progression or even the members are unable to tolerate the study drugs.For all circulation cytometry experiments, ten,000 cells per replicate were being analyzed, a